Abstract
Using a highly sensitive allele-specific polymerase chain reaction assay we detected the M184V mutation for lamivudine resistance in plasma from 9.4% of HIV-1-infected pregnant women enrolled in the Women and Infant Transmission Study between 1998 and 2004. The prevalence of nelfinavir resistance (D30N) was 6.3%. These results suggest a high prevalence of primary lamivudine and nelfinavir resistance among HIV-1-infected pregnant women in the United States, and support routine genotypic resistance testing before initiating mother-to-child-transmission prophylaxis.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Drug Resistance, Viral / genetics*
-
Female
-
HIV Infections / drug therapy*
-
HIV Infections / prevention & control
-
HIV Infections / transmission
-
HIV Protease Inhibitors / pharmacology*
-
HIV-1 / drug effects*
-
HIV-1 / genetics
-
Humans
-
Infectious Disease Transmission, Vertical / prevention & control
-
Lamivudine / pharmacology*
-
Mutation
-
Nelfinavir / pharmacology*
-
Pregnancy
-
Pregnancy Complications, Infectious / prevention & control
-
Pregnancy Complications, Infectious / virology*
-
Prevalence
-
Reverse Transcriptase Inhibitors / pharmacology*
-
United States / epidemiology
Substances
-
HIV Protease Inhibitors
-
Reverse Transcriptase Inhibitors
-
Lamivudine
-
Nelfinavir